SG Americas Securities LLC Purchases New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

SG Americas Securities LLC purchased a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,445 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,173,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Savant Capital LLC bought a new position in Jazz Pharmaceuticals during the fourth quarter valued at about $272,000. New York State Teachers Retirement System increased its stake in Jazz Pharmaceuticals by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 43,847 shares of the specialty pharmaceutical company’s stock valued at $5,400,000 after acquiring an additional 529 shares during the period. Blue Trust Inc. increased its stake in Jazz Pharmaceuticals by 73.7% during the fourth quarter. Blue Trust Inc. now owns 1,767 shares of the specialty pharmaceutical company’s stock valued at $218,000 after acquiring an additional 750 shares during the period. Rhumbline Advisers increased its stake in Jazz Pharmaceuticals by 1.1% during the fourth quarter. Rhumbline Advisers now owns 167,560 shares of the specialty pharmaceutical company’s stock valued at $20,635,000 after acquiring an additional 1,755 shares during the period. Finally, Philip James Wealth Mangement LLC increased its stake in Jazz Pharmaceuticals by 43.0% during the fourth quarter. Philip James Wealth Mangement LLC now owns 10,659 shares of the specialty pharmaceutical company’s stock valued at $1,313,000 after acquiring an additional 3,205 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Seamus Mulligan acquired 1,621 shares of the firm’s stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company’s stock, valued at approximately $10,466,963. This represents a 1.62% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer now owns 439,307 shares in the company, valued at $51,113,369.45. This represents a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,000 shares of company stock worth $355,925. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Up 1.1%

NASDAQ JAZZ opened at $109.64 on Tuesday. The firm has a market cap of $6.63 billion, a PE ratio of 15.44, a price-to-earnings-growth ratio of 1.04 and a beta of 0.33. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The stock’s 50 day simple moving average is $107.97 and its 200 day simple moving average is $120.45. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million during the quarter, compared to the consensus estimate of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.68 earnings per share. As a group, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

JAZZ has been the subject of a number of recent research reports. Wall Street Zen cut Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 15th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Finally, Piper Sandler reissued an “overweight” rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.